Composition for skin improvement

Abstract

The present invention relates to a skin-improving composition comprising Cedrol; and one or more selected from the group consisting of Beta-sitosterol and Linoleic acid; or Ferulic acid; and one or more selected from the group consisting of Beta-sitosterol and Linoleic acid, in particular, to a skin-whitening, antioxidant; skin elasticity-enhancing or wrinkle-improving or skin-moisturizing cosmetic, food and quasi-drug composition comprising the above composition as an effective ingredient. In addition, the composition of the present invention improves the low-dosage stability of Cedrol and Ferulic acid, and confirms that, when combined with one or more selected from the group consisting of Beta-sitosterol and Linoleic acid, the effects of antioxidant, melanin reduction, collagen synthesis promotion, and hyaluronic acid synthesis promotion all produce synergistic effects compared to Cedrol; or Ferulic acid alone.

Description

Technical Field

[0001] This invention relates to skin-improving compositions comprising cedrol; and one or more selected from the group consisting of β-sitosterol and linoleic acid; or ferulic acid; and one or more selected from the group consisting of β-sitosterol and linoleic acid. Specifically, it relates to skin-whitening, antioxidant, skin-elasticity-enhancing or wrinkle-improving, or skin-moisturizing cosmetic, food, and tertiary pharmaceutical compositions containing the above compositions as active ingredients. Background Technology

[0002] A person's skin color is determined by a variety of factors, including the activity of melanocytes, the distribution of blood vessels, skin thickness, and the presence of pigments inside and outside the body. Melanin, the melanin produced by enzymes such as tyrosinase within melanocytes, is particularly important. Melanin exists in the skin and plays a vital role in protecting the body from damage caused by ultraviolet radiation. However, excessive production can promote pigmentation and skin aging, and it also plays a major role in inducing skin cancer.

[0003] To treat or reduce excessive melanin pigmentation, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione, and substances with tyrosinase inhibitory activity have traditionally been formulated with cosmetics or pharmaceuticals. However, their use has been limited due to insufficient whitening effects, skin safety concerns, and stability issues when formulated with cosmetics.

[0004] In addition, recent environmental pollution leading to increased ultraviolet radiation, Westernized lifestyles, and stress are increasing factors that threaten skin health. These can trigger skin pollution, dryness, problems, and abnormalities in the skin's immune system, ultimately leading to dermatitis, roughness, and rapid aging.

[0005] In particular, increasing the concentration of reactive oxygen species (ROS) in the body can lead to skin aging. These ROS attack lipids, proteins, sugars, and DNA, which are cellular building blocks, causing peroxidation. Therefore, there is a need to develop cosmetic compositions that have antioxidant effects that inhibit ROS generation, thereby providing anti-aging (preventing skin aging) effects.

[0006] Collagen is the main matrix protein produced in fibroblasts of the skin, playing a vital role in maintaining the skin's mechanical strength and tissue cohesion, supporting cell adhesion, and inducing cell differentiation. Due to aging and photoaging caused by ultraviolet radiation, collagen production decreases, and the activity of collagenases, which break down collagen, further promotes this reduction. This is reportedly closely related to the formation of wrinkles.

[0007] On the other hand, it is known that over 50% of the hyaluronic acid found in mammals is distributed in the skin, particularly in the intercellular spaces of the epidermis and the connective tissue of the dermis. It is understood that the amount of hyaluronic acid in the skin decreases with age, and this reduction is considered one of the direct causes of decreased skin moisture content. Therefore, skin hydration is closely related to hyaluronic acid.

[0008] Currently, retinol, adenosine, and chlorella extract are known cosmetic ingredients for enhancing skin elasticity and improving wrinkles. Retinol is a substance that promotes collagen synthesis and inhibits elastase, but its use is limited due to its instability and safety concerns such as irritation and rashes when applied to the skin.

[0009] In addition, cedrol or ferulic acid are well known for their cosmetic effects, but due to the inherent characteristics of substances such as solubility, it is difficult to fully deliver these effects through dosage forms. Summary of the Invention

[0010] Technical issues

[0011] To achieve the above objectives, through in-depth research, the inventors confirmed that when cedrol or ferulic acid is combined with one or more of the group consisting of β-sitosterol and linoleic acid, it has the effects of scavenging free radicals, reducing melanin, promoting collagen synthesis, and promoting hyaluronic acid synthesis. Furthermore, compared to preparing dosage forms using cedrol or ferulic acid alone, the stability of the dosage form is ensured by combining cedrol or ferulic acid with one or more of the group consisting of β-sitosterol and linoleic acid, thus completing this invention.

[0012] Problem-solving methods

[0013] To achieve the above objectives, the present invention provides a skin-improving composition for use in cosmetics, food or pharmaceutical products, comprising cedrol; and one or more selected from the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0014] In addition, the present invention provides a skin-improving composition for use in cosmetics, food or pharmaceutical products, comprising ferulic acid; and one or more selected from the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0015] To achieve the above objectives, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of treating the skin with a composition containing cedrol and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0016] To achieve the above objectives, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of administering to a subject a composition containing cedrol; and one or more of the group consisting of beta-sitosterol and linoleic acid as active ingredients.

[0017] To achieve the above objectives, a composition comprising cedrol and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients is provided for use in the preparation of cosmetics for skin whitening, anti-oxidation, skin elasticity enhancement or wrinkle improvement, or skin moisturizing; food; or quasi-medicinal products.

[0018] To achieve the above objectives, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of treating the skin with a composition containing ferulic acid and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0019] To achieve the above objectives, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of administering a composition containing ferulic acid and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients to a subject.

[0020] To achieve the above objectives, a composition comprising ferulic acid and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients is provided for use in the preparation of cosmetics for skin whitening, anti-oxidation, skin elasticity enhancement or wrinkle improvement, or skin moisturizing; food; or quasi-medicinal products.

[0021] Invention Effects

[0022] The compositions according to the present invention can improve the skin by eliminating free radicals, reducing melanin, promoting collagen synthesis, and promoting hyaluronic acid synthesis. Furthermore, since the compositions of the present invention have the effect of ensuring dosage form stability, they can be effectively used in cosmetics, food, or quasi-medicinal products for improving the skin. Detailed Implementation

[0023] The present invention will be described in detail below.

[0024] As confirmed in the experimental examples of this invention, when cedrol or ferulic acid is used alone to prepare dosage forms, there is a problem of rather low dosage form stability (Examples 7 and 11 of Experimental Example 2). However, for Examples 8 to 10 and Examples 12 to 14, in which cedrol or ferulic acid is combined with one or more of the group consisting of β-sitosterol and linoleic acid, it was confirmed that cedrol or ferulic acid did not precipitate. Therefore, it was confirmed that the dosage form stability is improved when combined with β-sitosterol and linoleic acid compared to when cedrol or ferulic acid is used alone.

[0025] Furthermore, it was confirmed that when combined with one or more of the groups selected from β-sitosterol and linoleic acid, the antioxidant, melanin-reducing, collagen-promoting, and hyaluronic acid-promoting effects were synergistic compared to cedrol or ferulic acid alone.

[0026] This invention provides a cosmetic, food, or quasi-pharmaceutical composition comprising cedrol and one or more selected from the group consisting of β-sitosterol and linoleic acid for skin whitening, anti-oxidation, skin elasticity enhancement, wrinkle improvement, or skin moisturizing.

[0027] On the other hand, a cosmetic, food, or quasi-pharmaceutical composition is provided, comprising ferulic acid and one or more selected from the group consisting of β-sitosterol and linoleic acid, for skin whitening, anti-oxidation, skin elasticity enhancement, wrinkle improvement, or skin moisturizing.

[0028] On the other hand, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of treating the skin with a composition containing cedrol and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0029] On the other hand, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of administering a composition containing cedrol and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients to a subject.

[0030] On the other hand, a composition comprising cedrol and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients is provided for use in the preparation of cosmetics for skin whitening, anti-oxidation, skin elasticity enhancement or wrinkle improvement, or skin moisturizing; food; or quasi-medicinal products.

[0031] On the other hand, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of treating the skin with a composition containing ferulic acid and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients.

[0032] On the other hand, a method is provided for whitening skin, providing antioxidant effects, enhancing skin elasticity, improving wrinkles, or moisturizing skin, comprising the step of administering a composition containing ferulic acid and one or more of the group consisting of β-sitosterol and linoleic acid as active ingredients to a subject.

[0033] On the other hand, a composition comprising ferulic acid and one or more selected from the group consisting of β-sitosterol and linoleic acid as active ingredients is provided for use in the preparation of cosmetics for skin whitening, anti-oxidation, skin elasticity enhancement or wrinkle improvement, or skin moisturizing; food; or quasi-medicinal products.

[0034] The "skin whitening" of this invention refers to not only inhibiting the synthesis of melanin to brighten skin tone, but also inhibiting or preventing melanin deposition in the skin (hyperpigmentation), and alleviating or improving chloasma and freckles caused by ultraviolet rays, hormones or genetics.

[0035] The "antioxidant" in this invention refers to the inhibition of cell oxidation by highly reactive free radicals or reactive oxygen species (ROS) caused by oxidative stress resulting from intracellular metabolism or ultraviolet radiation. Furthermore, by removing free radicals or ROS, cell damage can be reduced, thereby exhibiting an anti-aging effect on the skin. In this invention, the effect of scavenging free radicals was confirmed through experimentally demonstrated reduction in DPPH.

[0036] In this invention, "free radical" refers to an atom or molecule with one unpaired electron. Hydrogen atoms, chlorine atoms, etc., are monatomic free radicals. Generally, a free radical refers to an inorganic or organic compound molecule that releases a proton, resulting in an unpaired electron in the residue. Reactive oxygen species (ROS) exhibit excellent chemical reactivity, and the free radicals they induce can affect various reactions in organisms, leading to aging and other problems. Organisms are frequently exposed to the harmful effects of free radicals, and these harmful effects gradually accumulate with increasing cell age, leading to various diseases. Therefore, free radical scavenging plays a crucial role in antioxidation.

[0037] In this invention, "enhanced skin elasticity" refers to alleviating the degree of skin sagging or looseness. Additionally, "wrinkle improvement" refers to preventing, inhibiting, or preventing the formation of wrinkles on the skin, or alleviating existing wrinkles. In this invention, the effects of enhancing skin elasticity and improving wrinkles were confirmed by confirming the effect of promoting collagen synthesis.

[0038] The "skin moisturizing" of this invention refers to increasing the skin's sense of moisture and inhibiting moisture loss, thereby maintaining a hydrated state. In this invention, the skin moisturizing effect was confirmed by demonstrating its effect of promoting hyaluronic acid synthesis.

[0039] The "cosmetic composition" of the present invention can be in the form of a general emulsifier or a soluble agent. For example, it can be in the form of a lotion such as a softening lotion or nourishing lotion, a lotion such as a facial lotion or body lotion, a cream such as a nourishing cream, moisturizing cream, or eye cream, a serum, a cosmetic ointment, a balm, a spray, a gel, a face mask, a sunscreen, a makeup base, a liquid, solid, or spray foundation, a powder, a makeup remover such as a cleansing cream, cleansing lotion, or cleansing oil, and a facial cleanser such as a cleansing foam, soap, or shower gel.

[0040] In addition, the compositions of the present invention may further contain adjuvants commonly used in the field of cosmetics, such as fatty substances, organic solvents, solubilizers, concentrates and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blocking agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, liposomes, or any other ingredients commonly used in cosmetics.

[0041] In the case of wash-off cosmetics such as makeup removers and facial cleansers, where the active ingredients remain on the skin for a short period, the aforementioned cosmetic formulations may contain a higher concentration of the composition of the present invention described above. Conversely, in the case of leave-on cosmetics such as lotions, emulsions, creams, and serums, where the active ingredients remain on the skin for a longer period, it is acceptable to contain a lower concentration of the composition of the present invention described above compared to wash-off cosmetics. Although not limited thereto, in one specific example of the present invention, the composition may contain 0.0001% to 10% (preferably 0.0001% to 1% by weight) of the composition of the present invention relative to the total weight of the composition. When the composition of the present invention contains less than 0.0001% by weight of the composition of the present invention described above, sufficient skin whitening, antioxidant, skin elasticity enhancement, wrinkle improvement, or skin moisturizing effects cannot be expected, and when it contains more than 10% by weight, undesirable reactions such as allergies or skin safety issues may occur; therefore, this is to prevent such problems.

[0042] The "food composition" of the present invention refers to a composition in which the above-described composition of the present invention is added to food materials such as beverages, teas, spices, chewing gum, and biscuits, or prepared into food products such as capsules, powders, or suspensions.

[0043] The above-mentioned food formulations can be consumed daily, so they can be expected to have effects such as skin whitening, antioxidant, enhancing skin elasticity or improving wrinkles, or moisturizing the skin, and are therefore very useful.

[0044] When using the compositions of the present invention as food additives, they can be added directly or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The amount of active ingredients mixed can be appropriately determined according to their intended use (preventive, health, or therapeutic treatment). Generally, when preparing food or beverages, the compositions of the present invention are added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, relative to the raw materials. However, in cases of long-term consumption for health and hygiene purposes or for health regulation purposes, the above amount can be below the above range.

[0045] There are no particular restrictions on the types of food mentioned above. Examples of foods for which the above substances may be added include meat, sausages, bread, chocolate, confectionery, snacks, biscuits, pizza, instant noodles, other noodle products, chewing gum, dairy products including ice cream, various soups, beverages, tea, oral liquids, alcoholic beverages, and vitamin complexes, as well as all health foods in the conventional sense.

[0046] When the food dosage form is a beverage, it can contain various flavoring agents or natural carbohydrates as additional ingredients, just like regular beverages. These natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin, cyclodextrin, xylitol, sorbitol, erythritol, and other sugar alcohols. As sweeteners, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame can be used. The proportion of these natural carbohydrates is typically about 0.01 to 0.04 g per 100 mL of the composition of the present invention, preferably about 0.02 to 0.03 g.

[0047] In addition to the above, food dosage forms may also contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonating agents used in carbonated beverages. Furthermore, food dosage forms may contain fruit pulp used in the preparation of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used alone or in combination. The proportions of these additives are not critical, but are generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

[0048] The "tertiary pharmaceutical composition" of this invention refers to an article intended for the diagnosis, treatment, relief, management, or prevention of diseases in humans or animals, but whose effects on the human body are less severe than those of pharmaceuticals. It refers to compositions of articles other than those in which the article is not an appliance, machine, or device, or those in which the article is intended to have a pharmacological effect on the structure and function of humans or animals. Articles intended for pharmaceutical use under the Pharmaceutical Affairs Law are excluded. As a specific example, this may include, but is not limited to, topical skin preparations, personal hygiene products, or oral preparations. Furthermore, the formulation method, dosage, method of use, and constituent components of the tertiary pharmaceutical composition can be appropriately selected from conventional techniques known in the art.

[0049] This invention provides a pharmaceutical composition for skin whitening, anti-oxidation, skin elasticity enhancement, wrinkle improvement, or skin moisturizing, comprising cedrol; and one or more selected from the group consisting of β-sitosterol and linoleic acid.

[0050] On the other hand, the present invention provides a pharmaceutical composition for skin whitening, anti-oxidation, skin elasticity enhancement or wrinkle improvement or skin moisturizing, comprising ferulic acid; and one or more selected from the group consisting of β-sitosterol and linoleic acid.

[0051] The "pharmaceutical composition" of the present invention can be taken orally or non-orally, and when the composition of the present invention described above is used as a pharmaceutical composition, it can be taken in the form of a general pharmaceutical preparation, such as various dosage forms for clinical use, both orally and non-orally. In the case of formulation, it can be prepared using commonly used fillers, expanders, binders, wetting agents, disintegrants, surfactants, etc., or diluents or excipients, but is not limited thereto.

[0052] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc. These solid dosage forms can be formulated by mixing at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., but are not limited thereto, into the pharmaceutical composition of the present invention.

[0053] In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. As oral liquid preparations, including suspensions, liquid formulations, emulsions, syrups, etc., in addition to water and liquid paraffin, which are commonly used as simple diluents, various excipients may be included, such as wetting agents, sweeteners, flavoring agents, preservatives, etc., but not limited to these.

[0054] Non-oral formulations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate can be used. As a base for suppositories, witepsol, macrogol, Tween 61, cocoa butter, laurinum, glycerin gelatin, etc., can be used, but are not limited to these.

[0055] Furthermore, the compositions of the present invention can be used to prepare cosmetic dosage forms. For these cosmetic dosage forms, the same applies as described in the preceding description regarding cosmetic dosage forms containing the compositions of the present invention.

[0056] Each of the aforementioned ingredients included in the compositions according to the present invention is preferably included in the compositions of the present invention within a range not exceeding the maximum usage specified in the regulations prescribed by national governments. For example, in the case of providing pharmaceutical compositions, the ingredients may be included in the present invention within the range of manufacturing methods, properties, usage amounts, etc., specified in the pharmacopoeias or pharmaceutical catalogues prescribed in Korea, the United States, Europe, Germany, Japan, China, etc. Furthermore, in the case of providing cosmetic compositions, the ingredients may be included in the cosmetic compositions of the present invention within a range not exceeding the maximum usage specified in the cosmetic safety-related laws prescribed by national governments or the "Cosmetic Safety Technical Specifications" prescribed by the Chinese government.

[0057] The present invention will be described in detail below through the following experimental examples. However, the following experimental examples are merely illustrative of the invention, and the scope of the invention is not limited to the following experimental examples. In addition, these experimental examples are only for the purpose of helping to understand the invention, and therefore the scope of the invention is not limited in any way by these examples.

[0058] Experiment 1: Confirming the effect on improving skin

[0059] [Table 1]

[0060] Comparative Example 1 Cedrol Comparative Example 2 Ferulic acid Comparative Example 3 β-sitosterol Comparative Example 4 Linoleic acid Example 1 Cedrol + β-sitosterol Example 2 Cedrol + Linoleic acid Example 3 Cedrol + Beta-sitosterol + Linoleic acid Example 4 Ferulic acid + β-sitosterol Example 5 Ferulic acid + Linoleic acid Example 6 Ferulic acid + β-sitosterol + linoleic acid

[0061] As described above, the corresponding components were dissolved in methanol to prepare the samples. The concentrations of each component in the samples were adjusted according to the experimental methods described in Examples 1 to 4 below.

[0062] <Experimental Example 1-1> Antioxidant Effects of Free Radical Scavenging

[0063] In Comparative Examples 1 to 4 and Examples 1 to 6, methanol was used as a solvent to prepare solutions with a concentration of each component of 0.5 mg / mL. To confirm the antioxidant effects of Comparative Examples 1 to 4 and Examples 1 to 6, the free radical scavenging ability was measured using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) method. DPPH, as a relatively stable free radical, exhibited maximum absorbance at 517 nm when present in its free radical state, but lost its absorbance when the free radical was scavenged. DPPH was used dissolved in methanol at a concentration of 0.12 mM.

[0064] Comparative Examples 1 to 4, Examples 1 to 6, and Trolox solutions of different concentrations (0.0125, 0.025, 0.05, 0.1, 0.2, 0.4, 0.8 mg / mL) were added in 100 μL to each well of a 24-well plate, and DPPH solution was added in 1,900 μL. The plates were incubated at room temperature in the dark for 1 hour, and the absorbance at 517 nm was measured using a BioTek EPOCH microplate reader. Calibration curves were constructed using the absorbance values ​​of the seven Trolox solutions at different concentrations. In this experiment, Trolox was used as an indicator to measure the antioxidant capacity of the samples, and the antioxidant capacity of each comparative example and example was compared to Trolox. By substituting the absorbance of the example solutions into the calibration curve, the degree of antioxidant effect shown by 1 mL of the corresponding example solution was expressed as Trolox μmol equivalent / mL, and is summarized in Table 2 below. The experiment was performed three times, and the average value was calculated and displayed.

[0065] [Table 2]

[0066]

[0067] As shown in Table 2 above, it is confirmed that all embodiments of the present invention have sufficient free radical scavenging ability.

[0068] <Experimental Examples 1-2> Whitening Effects Caused by Inhibiting Melanin Production

[0069] To culture MNT-1 melanoma cells, a mixture of DMEM (Dulbecco's Modified Eagle's Medium) and 10% FBS (Fetal Bovine Serum) was used as the basal medium. MNT-1 melanoma cells were cultured at a concentration of 1–2 x 10⁻⁶ cells / mL. 5Cells were divided into 6-well plates at a concentration of 1 cell / mL and cultured for 24 hours. The samples were treated to bring the final concentrations of each component of Comparative Examples 1-4 and Examples 1-6 to 3 μg / mL (3 ppm), and then cultured for 72 hours. As a positive control, arbutin was applied to achieve a concentration of 200 μg / mL (200 ppm) (positive control in Table 3). Cells were then treated with trypsin, removed from the culture vessel, centrifuged at 13,000 rpm for 1 minute, and the supernatant was removed. 300 μL of 0.5% Triton X-100 solution was added to the remaining cells to lyse them. The cells were then centrifuged again at 13,000 rpm for 3 minutes to recover the pellet and supernatant, respectively. 100 μL of 0.5 N sodium hydroxide solution was added and incubated for 12 hours to dissolve the melanin in the precipitate, and the total amount of melanin generated was measured by measuring the absorbance at 450 nm using a spectrophotometer.

[0070] The total amount of melanin production inhibited compared to the group treated with methanol (negative control group) was calculated as the melanin production inhibition rate (%) (Equation 1 below). The experiment was conducted 3 times, and the average value was calculated and shown in Table 3.

[0071] Melanin production inhibition rate (%) = (1 - (total melanin produced by the groups treated with each sample / total melanin produced by the group treated with methanol)) * 100 (Equation 1)

[0072] [Table 3]

[0073]

[0074] As shown in Table 3 above, it has been confirmed that the embodiments of the present invention have a sufficient melanin production inhibition effect.

[0075] <Experimental Examples 1-3> Effects on Promoting Collagen Synthesis

[0076] *To culture 76 human fibroblasts, a mixture of DMEM and 10% FBS was used as the basal medium. Skin fibroblasts were cultured at a concentration of 2–5 x 10⁶ cells / mL. 4Cells were divided into 48-well plates at a concentration of 1 cell / mL and cultured for 24 hours. The basal medium containing growth factors was removed, and medium (without FBS) containing the final concentration of each component from Comparative Examples 1-4 and Examples 1-6 was added, and the cells were cultured for 24 hours. The positive control group for inducing collagen synthesis was treated with TGF-β to achieve a concentration of 5 ng / mL (5 ppb) (positive control group in Table 4). Cell culture was collected, and the synthesized collagen was measured using a Human Precollagen 1α1 Duoset ELISA Kit (R&D Systems) and a spectrophotometer.

[0077] The isolated and purified collagen was measured at concentrations of 0.25, 0.5, 1, 2, 4, and 8 ng / mL to create calibration curves. Based on these curves, the amount of collagen (Type I collagen) generated in Comparative Examples 1 to 4, Examples 1 to 6, the negative control group, and the positive control group was calculated. The amount of collagen generated compared to the group treated with methanol (negative control group) was calculated as the collagen generation rate (%) (Equation 2). The experiment was performed three times, and the average value was calculated and shown in Table 4.

[0078] Collagen production rate (%) = (Collagen production of the group treated with each example - Collagen production of the group treated with methanol) / (Collagen production of the group treated with methanol) * 100 (Equation 2)

[0079] [Table 4]

[0080]

[0081] As shown in Table 4 above, a sufficient collagen-enhancing effect was confirmed in all embodiments of the present invention.

[0082] <Experimental Examples 1-4> Effects on promoting hyaluronic acid synthesis

[0083] Primary cultured human skin keratinocytes were purchased from Thermo Fisher Scientific and cultured using keratinocyte-SFM (SFM) cells supplemented with epidermal growth factor (EGF) and bovine pituitary extract (BPE). The keratinocytes were cultured at a density of 2–5 x 10⁻⁶ cells / mL. 5Cells were cultured at a concentration of 100 cells / mL into 60-mm culture plates and cultured for 24 hours. The basal medium containing growth factors was removed, and medium (without EGF and BPE) containing the final concentrations of each component from Comparative Examples 1-4 and Examples 1-6 was added and cultured for 24 hours. The positive control group for induced hyaluronic acid synthesis was treated with all-trans-retinoic acid to reach 100 nM (positive control group in Table 5). Cell culture was collected, and the synthesized hyaluronic acid was measured using a Hyaluronan DuoSet ELISA kit (R&D Systems) and a spectrophotometer.

[0084] Standard hyaluronic acid was measured at concentrations of 1.1, 3.3, 10, 30, and 90 ng / mL to create calibration curves. Based on these curves, the hyaluronic acid production amounts of Comparative Examples 1 to 4, Examples 1 to 6, the negative control group, and Comparative Example 3 were calculated. The amount of hyaluronic acid produced compared to the group treated with methanol (negative control group) was calculated as the hyaluronic acid production rate (%) (Equation 3). The experiment was performed three times, and the average value was calculated and shown in Table 5.

[0085] Hyaluronic acid production rate (%) = (Hyaluronic acid production of the group treated with the example - Hyaluronic acid production of the group treated with methanol) / (Hyaluronic acid production of the group treated with methanol) * 100 (Equation 3)

[0086] [Table 5]

[0087]

[0088] As shown in Table 5 above, it was confirmed that all embodiments of the present invention have sufficient hyaluronic acid generation effect.

[0089] Experimental Example 2: Confirmation of Improved Dosage Form Stability

[0090] <Experimental Example 2-1> Preparation of cosmetic compositions containing cedrol (Examples 7-10)

[0091] In Example 7, raw materials 3 and 4 were dispersed in raw material 2 according to the composition ratios (by weight %) listed in Table 6 below, and then raw material 5 was added and dissolved. After confirming dissolution, raw materials 6-8 were dissolved and then stirred evenly. Raw materials 9-11 were added to raw material 1 sequentially and stirred evenly. The ethanol phase was gradually added to the aqueous phase and stirred evenly for 10 minutes to prepare the beauty solution. Examples 8-10 were prepared using the same method as in Example 7.

[0092] [Table 6]

[0093]

[0094] <Experimental Example 2-2> Preparation of cosmetic compositions containing ferulic acid (Examples 11-14)

[0095] In Example 11, raw materials 3 and 4 were dispersed in raw material 2 according to the composition ratios (by weight %) listed in Table 7 below, and then raw material 5 was added and dissolved. After confirming dissolution, raw materials 6-8 were dissolved and then stirred evenly. Raw materials 9-11 were added to raw material 1 sequentially and stirred evenly. The ethanol phase was gradually added to the aqueous phase and stirred evenly for 10 minutes to prepare the beauty solution. Examples 12-14 were prepared using the same method as in Example 11.

[0096] [Table 7]

[0097]

[0098]

[0099] <Experimental Example 2-3> Evaluating Solubility and Compatibility

[0100] For the cosmetic compositions of Examples 7 to 14 above, solubility and compatibility were evaluated. During storage at 25°C for 4 weeks, 4°C for 4 weeks, and 45°C for 4 weeks, phase separation and precipitation were observed visually and are shown in Tables 8 and 9 below.

[0101] <Evaluation Criteria>

[0102] No abnormalities: ○, slight precipitation: △, separation and precipitation: ×

[0103] [Table 8]

[0104] Room temperature (25℃) X △ ○ ○ Refrigerate (4℃) △ ○ ○ ○ High temperature (45℃) X ○ ○ ○

[0105] As shown in Table 8 above, for Examples 8 to 10 using β-sitosterol and linoleic acid, cedrol was confirmed to be soluble in water. For Example 7 without using β-sitosterol and linoleic acid, it was confirmed to be dispersed intact in powder form and not soluble.

[0106] [Table 9]

[0107] Room temperature (25℃) X ○ ○ ○ Refrigerate (4℃) X △ △ ○ High temperature (45℃) X ○ ○ ○

[0108] As shown in Table 9 above, for Examples 12 to 14, which used β-sitosterol and linoleic acid, ferulic acid was confirmed to be soluble in water. In Example 14, which used both β-sitosterol and linoleic acid, a dosage form that remained stable even under refrigeration conditions was confirmed to be free of precipitation. For Example 11, which did not use β-sitosterol and linoleic acid, it was confirmed to be dispersed intact in powder form and not soluble.

[0109] The above experimental results confirm the following fact: the β-sitosterol and linoleic acid of the present invention affect the solubility of cedrol and ferulic acid, thereby helping to ensure stable dispersion in cosmetics.

[0110] Furthermore, it can be confirmed that the cedrol and ferulic acid of the present invention can be stably dispersed in cosmetics when treated with β-sitosterol and linoleic acid, respectively.

Claims

1. Use of a composition comprising cedrol and one or more of the group consisting of β-sitosterol and linoleic acid in the preparation of a cosmetic having improved dosage form stability.

2. The use according to claim 1, wherein, The cosmetic ingredients are in the form of lotions, serums, lotions, creams, masks, gels, powders, ointments, or cleansers.

3. The use according to claim 1, wherein, The composition has the effects of reducing melanin, scavenging free radicals, promoting collagen synthesis, and promoting hyaluronic acid synthesis.

Images